• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Argentina Pharmaceuticals and Healthcare Report Q2 2008 - Product Image

Argentina Pharmaceuticals and Healthcare Report Q2 2008

  • Published: March 2008
  • Region: Argentina
  • 71 pages
  • Business Monitor International

The Argentina Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Argentinas pharmaceuticals and healthcare industry.

After posting an estimated 12.0% year-on-year (y-o-y) growth in US dollar terms in 2007, BMI forecasts that the Argentine pharmaceutical market will grow at a more modest 8.0% pace in 2008. Last year’s market growth was somewhat distorted by a weak Q106 in relation to Q107, along with some frontloaded spending in H107 ahead of presidential elections later in the year. We expect growth to be smoother in 2008, although BMI’s forecast is more conservative than local numbers, due to our broader scepticism regarding market regulation and efficiency of spending in the healthcare system.

For the pharmaceutical market, domestic production grew in lockstep with value consumption in the country, although a primary driver for growth in 2007 was exports, estimated by trade group COOPERARLA at around US$700mn last year, a record amount since the 2001-2002 financial crisis. Continued infusions of cash by the Brazilian government into public healthcare, and broader positive growth dynamics in Latin America - READ MORE >

Executive Summary .........5
Argentina Pharmaceuticals And Healthcare Industry SWOT ............................................................................................................................... 6
Argentina Political SWOT ..................................................... 7
Argentina Economic SWOT ................................................... 8
Argentina Business Environment SWOT................................ 9
Pharmaceutical Business Environment Ratings ........................................................................................10
Table: Pharmaceutical Business Environment Rankings..... 10
Limits To Potential Returns ................................................. 10
Risks To Realisation Of Returns .......................................... 11
Argentina - Market Summary .......................................................................................................................12
Regulatory Regime.........15
Intellectual Property Environment....................................... 15
Table: Joint Declaration By Latin American Health Ministers, May 2006.......................................................................................................... 18
Pricing And Reimbursement Issues...................................... 19
Table: Argentina’s Drug Price Freeze, 2005-2007.............. 20
Other Regulatory Issues....................................................... 22
Industry Developments..24
Healthcare Sector ................................................................ 24
Medical Devices................................................................... 25
Pharmaceutical Sector - Market Performance .................... 25
Retail Pharmacy Sector ....................................................... 27
Multinational Sector Developments ..................................... 28
Domestic Manufacturing Sector .......................................... 31
Vaccines Sector.................................................................... 33
Industry Forecast Scenario ...........................................................................................................................35
Overall Market Forecast...................................................... 35
Table: Drug Market Indicators, 2006-2012......................... 36
Key Growth Factors - Industry............................................ 36
Key Growth Factors - Macroeconomic ............................... 37
Table: Argentina - Economic Activity ................................. 39
Prescription Market Forecast .............................................. 40
Table: Prescription Drug Market Indicators (US$mn unless otherwise stated)................................................................................................... 41
Non-Prescription Market Forecast ...................................... 41
Advertising........................................................................... 42
Competitive Landscape - OTC Pharmaceuticals................. 42
Table: OTC Market Indicators, 2005-2012 (US$mn unless otherwise stated) ..................................................................................................... 43
Generics Market Forecast ................................................... 44
Table: Generics And Patented Market Indicators, 2006-2 45
Export/Import Forecasts...................................................... 46
Table: Import And Export Trade Indicators, 2006-2012 (US$mn) ...................................................................................................................... 47
Other Healthcare Data Forecasts........................................ 48
Table: Socio-Demographic Indicators, 2005-2012.............. 48
Key Risks To our Forecast Scenario................................ 48
Competitive Landscape.49
Company Monitor...........50
Leading Foreign Companies..................................................... 50
Pfizer ................................................................................... 50
Roche................................................................................... 52
Novartis ............................................................................... 54
GlaxoSmithKline (GSK)....................................................... 55
Sanofi-Aventis...................................................................... 56
Merck & Co ......................................................................... 58
Boehringer Ingelheim .......................................................... 60
Indigenous Manufacturers ........................................................ 62
Laboratorios Roemmers....................................................... 62
Laboratorios Bagó............................................................... 64
BMI Forecast Modelling.67
How We Generate Our Industry Forecasts ............................... 67
Pharmaceutical Industry........................................................... 68
Pharmaceutical Business Environment Ratings Methodology .. 68
Ratings Overview................................................................. 68
Table: Pharmaceutical Business Environment Indicators ... 69
Sources ..................................................................................... 70

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos